1-3 of 3
Taku Seriu
Close
Sort by
Journal Articles

Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.

Michinori Ogura, MD, PhD, Hirohisa Nakamae, MD, PhD, Shin Fujisawa, MD, PhD, Kenichi Ishizawa, MD, Masafumi Taniwaki, MD, PhD, Atae Utsunomiya, MD, PhD, Kosei Matsue, MD, PhD, Kazuo Tamura, MD, Kensuke Usuki, MD, PhD, Mitsune Tanimoto, MD, PhD, Yoji Ishida, MD, PhD, Hideki Akiyama, MD, PhD, Rika Sakai, MD, PhD, Masanobu Kasai, MD, PhD, Masayuki Hino, MD, PhD, Kyoji Ueda, MD, PhD, Taku Seriu, MD, PhD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD
Journal: Blood
Blood (2010) 116 (21): 4484.
https://doi.org/10.1182/blood.V116.21.4484.4484
Published: 2010
Journal Articles

Dasatinib (SPRYCEL®, BMS-354825) Phase-I/II Study of Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib: Results of the CA180031 Study in Japan (Phase I Portion).

Hisashi Sakamaki, Shin Fujisawa, Kensei Tobinai, Masafumi Taniwaki, Shuichi Miyawaki, Itsuro Jinnai, Atae Utsunomiya, Mistune Tanimoto, Yasuo Morishima, Masaya Okada, Yasushi Miyazaki, Nobuhiko Uoshima, Taku Seriu, Ryuzo Ohno
Journal: Blood
Blood (2006) 108 (11): 4809.
https://doi.org/10.1182/blood.V108.11.4809.4809
Published: 2006
Journal Articles

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Clinical Trials & Observations
Marja J. Willemse, Taku Seriu, Klaudia Hettinger, Elisabetta d'Aniello, Wim C. J. Hop, E. Renate Panzer-Grümayer, Andrea Biondi, Martin Schrappe, Willem A. Kamps, Guiseppe Masera, Helmut Gadner, Hansjoerg Riehm, Claus R. Bartram, Jacques J. M. van Dongen
Journal: Blood
Blood (2002) 99 (12): 4386–4393.
https://doi.org/10.1182/blood.V99.12.4386
Published: 2002